NCT03682653View on ClinicalTrials.gov

Neonates and Azithromycin, an Innovation in the Treatment of Children in Burkina Faso

PHASE4CompletedINTERVENTIONAL
Enrollment

21,832

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

May 1, 2022

Study Completion Date

December 31, 2022

Conditions
Childhood Mortality
Interventions
DRUG

Azithromycin

a single dose of Azithromycin will be administered to infants between their 8-27th days of life

DRUG

Placebo

a single dose of Placebo will be administered to infants between their 8-27th days of life

Trial Locations (1)

BP 02

Centre de Recherche En Santé de Nouna, Nouna

All Listed Sponsors
collaborator

Centre de Recherche en Sante de Nouna, Burkina Faso

OTHER_GOV

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

University of California, San Francisco

OTHER

NCT03682653 - Neonates and Azithromycin, an Innovation in the Treatment of Children in Burkina Faso | Biotech Hunter | Biotech Hunter